Transcatheter Arterial Chemoembolization Based on Hepatic Hemodynamics for Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer-related deaths in the world. The Barcelona Clinic Liver Cancer (BCLC) classification has recently emerged as the standard classification system for clinical management of patients with HCC. According...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1155/2013/479805 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832558777043255296 |
|---|---|
| author | Satoru Murata Takahiko Mine Tatsuo Ueda Ken Nakazawa Shiro Onozawa Daisuke Yasui Shin-ichiro Kumita |
| author_facet | Satoru Murata Takahiko Mine Tatsuo Ueda Ken Nakazawa Shiro Onozawa Daisuke Yasui Shin-ichiro Kumita |
| author_sort | Satoru Murata |
| collection | DOAJ |
| description | Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer-related deaths in the world. The Barcelona Clinic Liver Cancer (BCLC) classification has recently emerged as the standard classification system for clinical management of patients with HCC. According to the BCLC staging system, curative therapies (resection, transplantation, and percutaneous ablation) can improve survival in HCC patients diagnosed at an early stage and offer potential long-term curative effects. Patients with intermediate-stage HCC benefit from transcatheter arterial chemoembolization (TACE), and those diagnosed at an advanced stage receive sorafenib, a multikinase inhibitor, or conservative therapy. Most patients receive palliative or conservative therapy only, and approximately 50% of patients with HCC are candidates for systemic therapy. TACE is often recommended for advanced-stage HCC patients all over the world because these patients desire therapy that is more effective than systemic chemotherapy or conservative treatment. This paper aims to summarize both the published data and important ongoing studies for TACE and to discuss technical improvements in TACE for advanced-stage HCC. |
| format | Article |
| id | doaj-art-14b1ae922f7d4793b0e9f7ed5d721fcd |
| institution | Kabale University |
| issn | 1537-744X |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Scientific World Journal |
| spelling | doaj-art-14b1ae922f7d4793b0e9f7ed5d721fcd2025-02-03T01:31:31ZengWileyThe Scientific World Journal1537-744X2013-01-01201310.1155/2013/479805479805Transcatheter Arterial Chemoembolization Based on Hepatic Hemodynamics for Hepatocellular CarcinomaSatoru Murata0Takahiko Mine1Tatsuo Ueda2Ken Nakazawa3Shiro Onozawa4Daisuke Yasui5Shin-ichiro Kumita6Department of Radiology, Center for Advanced Medical Technology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8602, JapanDepartment of Radiology, Center for Advanced Medical Technology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8602, JapanDepartment of Radiology, Center for Advanced Medical Technology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8602, JapanDepartment of Radiology, Center for Advanced Medical Technology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8602, JapanDepartment of Radiology, Center for Advanced Medical Technology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8602, JapanDepartment of Radiology, Center for Advanced Medical Technology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8602, JapanDepartment of Radiology, Center for Advanced Medical Technology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8602, JapanHepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer-related deaths in the world. The Barcelona Clinic Liver Cancer (BCLC) classification has recently emerged as the standard classification system for clinical management of patients with HCC. According to the BCLC staging system, curative therapies (resection, transplantation, and percutaneous ablation) can improve survival in HCC patients diagnosed at an early stage and offer potential long-term curative effects. Patients with intermediate-stage HCC benefit from transcatheter arterial chemoembolization (TACE), and those diagnosed at an advanced stage receive sorafenib, a multikinase inhibitor, or conservative therapy. Most patients receive palliative or conservative therapy only, and approximately 50% of patients with HCC are candidates for systemic therapy. TACE is often recommended for advanced-stage HCC patients all over the world because these patients desire therapy that is more effective than systemic chemotherapy or conservative treatment. This paper aims to summarize both the published data and important ongoing studies for TACE and to discuss technical improvements in TACE for advanced-stage HCC.http://dx.doi.org/10.1155/2013/479805 |
| spellingShingle | Satoru Murata Takahiko Mine Tatsuo Ueda Ken Nakazawa Shiro Onozawa Daisuke Yasui Shin-ichiro Kumita Transcatheter Arterial Chemoembolization Based on Hepatic Hemodynamics for Hepatocellular Carcinoma The Scientific World Journal |
| title | Transcatheter Arterial Chemoembolization Based on Hepatic Hemodynamics for Hepatocellular Carcinoma |
| title_full | Transcatheter Arterial Chemoembolization Based on Hepatic Hemodynamics for Hepatocellular Carcinoma |
| title_fullStr | Transcatheter Arterial Chemoembolization Based on Hepatic Hemodynamics for Hepatocellular Carcinoma |
| title_full_unstemmed | Transcatheter Arterial Chemoembolization Based on Hepatic Hemodynamics for Hepatocellular Carcinoma |
| title_short | Transcatheter Arterial Chemoembolization Based on Hepatic Hemodynamics for Hepatocellular Carcinoma |
| title_sort | transcatheter arterial chemoembolization based on hepatic hemodynamics for hepatocellular carcinoma |
| url | http://dx.doi.org/10.1155/2013/479805 |
| work_keys_str_mv | AT satorumurata transcatheterarterialchemoembolizationbasedonhepatichemodynamicsforhepatocellularcarcinoma AT takahikomine transcatheterarterialchemoembolizationbasedonhepatichemodynamicsforhepatocellularcarcinoma AT tatsuoueda transcatheterarterialchemoembolizationbasedonhepatichemodynamicsforhepatocellularcarcinoma AT kennakazawa transcatheterarterialchemoembolizationbasedonhepatichemodynamicsforhepatocellularcarcinoma AT shiroonozawa transcatheterarterialchemoembolizationbasedonhepatichemodynamicsforhepatocellularcarcinoma AT daisukeyasui transcatheterarterialchemoembolizationbasedonhepatichemodynamicsforhepatocellularcarcinoma AT shinichirokumita transcatheterarterialchemoembolizationbasedonhepatichemodynamicsforhepatocellularcarcinoma |